Neos Therapeutics- a Grand Prairie-based biotech startup known for its fruit-flavored drug akin to Adderall, has reported a loss of $18.4 million in the fourth quarter.The pharmaceutical company posted a total net product revenue of $3.5 million in the period, compared to $1.7 million for the fourth quarter of 2015. Neos also reported that its loss had widened to $83.3 million for the year, which leadership attributed to marketing costs.The company gained recognition in 2016 when the U.S. Food and Drug Administration approved Adzenys XR-ODT, the first extended-release orally disintegrating tablet to treat attention deficit hyperactivity disorder. Continue reading...
Copyright The Dallas Morning News